The addition of bevacizumab to currently available treatment options for metastatic colorectal cancer has changed the traditional chemotherapy-based paradigm. In this review we cover published clinical trials pertaining to the toxicity and efficacy of bevacizumab for metastatic colorectal cancer. Several randomized trials have studied combinations of irinotecan, oxaliplatin, 5-fluorouracil or capecitabine with bevacizumab. Efficacy in terms of progressionfree survival and overall survival has been improved to varying degrees with the addition of bevacizumab. Bevacizumab's distinctive toxicity profile has been well demonstrated in these trials, and has been shown to be manageable. However, certain patient groups, such as the elderly, may require particular toxicity considerations with bevacizumab. The optimal timing, dose and duration of bevacizumab-containing therapy have yet to be fully determined. Further randomized data, particularly for patients with potentially resectable liver metastases, are required in order to fully define the role of bevacizumab in the increasingly complex management paradigm for this disease.
Introduction
Bevacizumab is a humanized recombinant monoclonal antibody directed at vascular endothelial growth factor A (VEGF-A) that has altered the therapeutic landscape for advanced colorectal cancer, and spawned an array of clinical trials seeking to optimize its use. While generally well tolerated, bevacizumab has a unique toxicity profile which needs to be considered in the context of a patient's comorbidities as well as the proposed chemotherapy backbone. There are several randomized clinical trials which are informative for both efficacy and toxicity of bevacizumabchemotherapy combinations, and these are presented in this review.
The goals of palliative therapy for advanced colorectal cancer are similar to those for other advanced epithelial malignancies in terms of improving quality of life (QOL) and survival. In the pre-bevacizumab era, successive clinical trials have demonstrated improved QOL and survival outcomes with more efficacious chemotherapy regimens [de Gramont et al. 2000; Cunningham and Glimelius, 1999] . In addition, with the increasing use of surgery for oligometastatic disease, another goal of chemotherapy is as an adjunct to metastasectomy in a bid to achieve medium-to long-term disease-free survival [Adam et al. 2009 [Adam et al. , 2001 Nordlinger et al. 2008] . A challenge for oncologists is to obtain maximum efficacy whilst minimizing the toxicity of bevacizumab-containing regimens for individual patients.
There are a number of potential mechanisms by which bevacizumab may exert antitumour effects. These include inhibition of new vessel growth, regression of newly formed tumour vasculature, 'normalization' of tumour blood flow and direct effects on tumour cells [Ellis, 2006] . Preclinical data demonstrated inhibition of tumour growth in colon cancer xenograft models by anti-VEGF antibodies [Warren et al. 1995; Kim et al. 1993] .
A phase I trial investigated bevacizumab doses up to 10 mg/kg in 25 patients with advanced malignancy [Gordon et al. 2001] . Adverse events including headache, hypertension and bleeding were observed, but dose-limiting toxicity did not occur.
With subsequent trials across several tumour types, clinical toxicities of bevacizumab have since been well described. More common effects include hypertension, proteinuria, bleeding, arterial and venous thromboembolism, and delayed wound healing. Risk factors such as prior arterial thrombo-embolic event (ATE) or age over 65 years may predispose to ATE during treatment with chemotherapy plus bevacizumab [Scappaticci et al. 2007 ]. In the same analysis, aspirin use was associated with a modest increase in the risk of grade 3/4 bleeding. Rarer events include reversible posterior leukoencephalopathy syndrome (RPLS) [Glusker et al. 2006 ]. Gastrointestinal perforation represents the severe end of the spectrum of impaired wound healing, and has been studied extensively, in particular with respect to risk stratification [Hapani et al. 2009 ].
Phase II and pivotal phase III clinical trials
The first randomized trial of bevacizumab in metastatic colorectal cancer was a three-arm phase II study of 104 previously untreated patients which evaluated two dose levels of bevacizumab [Kabbinavar et al. 2003 ]. They were randomized to fluorouracil (5-FU)/leucovorin (LV), 5-FU/LV plus bevacizumab 5 mg/kg or 5-FU/LV plus bevacizumab 10 mg/kg. Response rates were 17% (control), 40% (bevacizumab 5 mg/kg, p ¼ 0.029) and 24% (bevacizumab 10 mg/kg, p ¼ 0.434). Median time-to-progression was 5.2 months (control), 9.0 months (5 mg/kg, p ¼ 0.005), 7.2 months (10 mg/kg, p ¼ 0.217). There were no episodes of grade 3/4 hypertension in the control group; 8.5% of patients in the bevacizumab 5 mg/kg group developed grade 3/4 hypertension compared with 25% of patients in the 10 mg/kg group. No instances of gastrointestinal perforation were reported. While the sample size was small, the bevacizumab dose selected for evaluation in subsequent clinical trials was 5 mg/kg every 2 weeks.
The pivotal AVF2107 phase III trial demonstrated improved survival in metastatic colorectal cancer by adding bevacizumab to chemotherapy [Hurwitz et al. 2004] : 813 previously untreated patients were randomized to irinotecan, 5-FU and LV (IFL) plus placebo or IFL plus bevacizumab 5 mg/kg every 2 weeks. The median survival was 15.6 months for IFL and 20.3 months for IFL plus bevacizumab with a hazard ratio (HR) of 0.66 (p < 0.001). Overall response rate was improved from 34.8% (IFL) to 44.8% (IFL plus bevacizumab), p ¼ 0.004. The 60-day all-cause mortality was similar for both arms: 4.9% for IFL and 3.0% for IFL plus bevacizumab. Grade 3 hypertension occurred in 2.3% of IFL-treated patients and 11.0% of IFL plus bevacizumab patients (p < 0.01). Gastrointestinal perforation occurred in 1.5% of patients who received bevacizumab compared with 0% of patients who did not receive bevacizumab. On the basis of these data, the US Food and Drug Administration (FDA) approved bevacizumab in 2004 as a firstline treatment for metastatic colorectal cancer in combination with chemotherapy.
The health-related QOL impact of adding bevacizumab to chemotherapy was examined for the aforementioned phase III trial as well as an earlier phase II trial which compared 5-FU/LV with 5-FU/LV plus bevacizumab. [Kabbinavar et al. 2008] Unfortunately, adequate QOL data were only available for 249 patients in the phase III trial. There was no statistically significant differences across three QOL instruments (Functional Assessment of Cancer TherapyColorectal (FACT-C) Colorectal Cancer Subscale (CCS), Trial Outcome Index and FACT-C total score), for time to deterioration in health-related QOL for the two treatment arms.
ECOG first and second-line trials
The Eastern Cooperative Oncology Group (ECOG) conducted a nonrandomized phase II trial (E2200) also using IFL as the chemotherapy backbone, together with high-dose bevacizumab 10 mg/kg every 2 weeks [Giantonio et al. 2006 ]. Ninety-two patients were enrolled, but only 81 were evaluable for efficacy. After the first 20 patients were treated, the chemotherapy doses were reduced by 20% as a result of a toxicity review of other trials. The response rate was 49.4%; median progression-free survival (PFS) was 10.7 months. Median survival was 26.3 months; 2.3% of patients experienced grade 3 hypertension, none had grade 4 hypertension. The rate of gastrointestinal perforation was 2.3%.
The next ECOG study was the three-arm E3200 trial, which studied the addition of bevacizumab to oxaliplatin, 5-FU, LV (FOLFOX4) as well as bevacizumab alone in patients with metastatic colorectal cancer previously treated with irinotecan and 5-FU but who were bevacizumab-naïve [Giantonio et al. 2007 ]. This trial also used bevacizumab 10 mg/kg rather than 5 mg/kg every 2 weeks. There were 829 patients randomized to treatment. Median survival was improved from 10.8 months (FOLFOX4 alone) to 12.9 months (FOLFOX4 plus bevacizumab) with a HR of 0.75 (p ¼ 0.0011). The median survival for the bevacizumab-alone arm was 10.2 months, which may reflect postprogression therapy in view of the brief PFS of 2.7 months. Overall response rates were 22.7% (FOLFOX4 plus bevacizumab, 8.6% (FOLFOX4), and 3.3% (bevacizumab) (p < 0.0001 for chemotherapy arms). The 60-day all-cause mortality was similar for both chemotherapy arms: 4% and 5% respectively. Grade 3/4 hypertension occurred in 1.8% of FOLFOX4 patients and 6.2% of FOLFOX4 plus bevacizumab patients, p ¼ 0.008. Three patients in each of the bevacizumab-containing arms experienced gastrointestinal perforation, whereas there were no episodes in the FOLFOX4-alone arm. In the FOLFOX4bevacizumab arm, 16.3% of patients experienced grade 3/4 neuropathy compared with 9.2% in the FOLFOX4 arm, p ¼ 0.011.
Third-line bevacizumab
A National Cancer Institute (NCI) Treatment Referral Centre trial TRC-0301 confirmed the minimal benefit of bevacizumab plus 5-FU/LV in a cohort of 350 patients who were oxaliplatin and irinotecan refractory [Chen et al. 2006 ]. The objective response rate was 1% in the first 100 patients, median PFS was 3.5 months and median survival was 9.0 months. The toxicity profile was similar to other trials.
Other randomized first-line trials
The BICC-C study was originally designed to compare different irinotecan-based regimens for the first-line treatment of metastatic colorectal cancer [Fuchs et al. 2007 ]. There were 430 patients randomized to one of three arms: irinotecan plus infused 5-FU/LV (FOLFIRI), irinotecan plus bolus 5-FU/LV (mIFL) and irinotecan plus capecitabine (CapeIRI). After a protocol amendment, an additional 117 patients were randomized to FOLFIRI plus bevacizumab 5 mg/kg every 2 weeks or mIFL plus bevacizumab 7.5 mg/ kg every 3 weeks, while the CapeIRI arm was discontinued. Updated data for the amended trial period showed that median survival was significantly superior in the FOLFIRI plus bevacizumab arm (28.0 months) versus mIFL plus bevacizumab (19.2 months), p ¼ 0.037 [Fuchs et al. 2008 ]. There were 12.5% of patients on the FOLFIRI plus bevacizumab arm who developed grade 3/4 hypertension compared with 1.7% on the mIFL plus bevacizumab arm.
A similar study (TREE) was conducted using oxaliplatin-based chemotherapy as first-line therapy for metastatic colorectal cancer [Hochster et al. 2008 ]. In the initial cohort (TREE-1), 150 patients were randomized to mFOLFOX6, oxaliplatin/bolus 5-FU (bFOL) or capecitabine/ oxaliplatin. Owing to emerging data, the protocol was amended to add bevacizumab to each chemotherapy regimen, and a further 223 patients were randomised to receive the corresponding regimens plus bevacizumab (TREE-2). The primary endpoint was the incidence of grade 3/4 toxicity during the first 12 weeks of treatment. In TREE-1, 59%, 36% and 67% of patients in the mFOLFOX6, bFOL, and CapeOx arms, respectively, experienced such toxicity. In TREE-2, the corresponding incidences were 59%, 51% and 56%. Sixty-day all-cause mortality was 3.4% (TREE-1) and 1.9% (TREE-2). The incidence of grade 3 neuropathy was similar between TREE-1 and TREE-2. There were five episodes of bowel perforation, two episodes of grade 3 bleeding and 13 episodes of grade 3/4 hypertension in TREE-2.
Median duration of therapy was similar for both cohorts: 1824 months (TREE-1) and 1924 months (TREE-2). The time-to-tumour progression (TTP) for TREE-1 was comparable across all arms: 8.7 months (FOLFOX), 6.9 months (bFOL), 5.9 months (CapeOx); for TREE-2 the TTPs were 9.9 months (FOLFOX/bevacizumab), 8.3 months (bFOL/bevacizumab), 10.3 months (CapeOx/bevacizumab), respectively. Median survival was 18.2 months for all TREE-1 patients and 23.7 months for the TREE-2 arms combined. There was no protocol-specified statistical comparison conducted between the two cohorts. Of note, while similar proportions of patients in TREE-1 and TREE-2 received subsequent anticancer therapy (69% versus 74%), more patients in the TREE-2 cohort received a biologic agent such as bevacizumab or cetuximab as part of subsequent therapy (38% versus 14%).
The randomized, phase III NO16966 study was originally designed to compare FOLFOX4 with capecitabine plus oxaliplatin (XELOX) for previously untreated patients with metastatic colorectal cancer [Saltz et al. 2008] . Following public release of the pivotal trial data, the study design was amended to a 2 Â 2 factorial design incorporating an additional randomization to compare the addition of bevacizumab to chemotherapy alone. There were 1401 patients randomized to receive FOLFOX4/XELOX plus placebo or FOLFOX/XELOX plus bevacizumab. Median PFS was 9.4 months for chemotherapy plus bevacizumab compared to 8.0 months for chemotherapy plus placebo, HR 0.83, p ¼ 0.0023. There was no difference in median survival between chemotherapy plus bevacizumab (21.3 months) and chemotherapy plus placebo (19.9 months), HR 0.89, p ¼ 0.077. There was also no difference in overall response rates: 38% versus 38%, p ¼ 0.99. The median duration on treatment was similar in the bevacizumab and placebo-containing arms (190 versus 176 days). Grade 3/4 hypertension occurred in 4% of bevacizumab patients and 1% of chemotherapy patients. Less than 1% of patients in either arm experienced gastrointestinal perforation. Thirty per cent of patients discontinued treatment due to adverse events in the chemotherapy plus bevacizumab arm compared with 21% of patients in the chemotherapy alone arm.
Observational studies: BEAT and BRiTE
The Bevacizumab Expanded Access Trial (BEAT) and Bevacizumab Regimens' Investigation of Treatment Effects (BRiTE) studies were nonrandomized prospective observational cohort studies which evaluated bevacizumab in combination with different chemotherapy regimens for previously untreated patients with metastatic colorectal cancer [Kozloff et al. 2009; Van Cutsem et al. 2009 ]. The overall median PFS and survival durations were similar to those described in randomized clinical trials. For the BEAT study comprising 1965 patients, the overall median PFS was 10.8 months with overall median survival of 22.7 months. In the BRiTE study of 1953 patients, the overall median PFS was 9.9 months with overall median survival of 22.9 months. Median PFS and survival were generally longer for patients receiving chemotherapy doublets compared with monotherapy plus bevacizumab, however, it should be noted that the chemotherapy regimens were selected by investigators and were not randomly allocated.
An analysis of the BRiTE study focused on treatment after first progression [Grothey et al. 2008b] . At the time of analysis, 1445 of the original 1953 patients had experienced disease progression and were divided into three groups: no further treatment (253 patients); no subsequent bevacizumab (531 patients); or subsequent bevacizumab-containing treatment (642 patients). Median survival durations were 12.6 months, 19.9 months and 31.8 months, respectively. A multivariate analysis confirmed postprogression bevacizumab as an independent predictor of survival postprogression. After adjustment for other prognostic factors, bevacizumab beyond progression (BBP) improved survival postprogression compared with no BBP (HR 0.49; 95% confidence interval 0.410.58; p < 0.001).
The incidence of bevacizumab-related toxicities also mirrored those reported in randomized clinical trials. Grade 3/4 hypertension occurred in 5% of patients on the BEAT study and 22% on the BRiTE study required antihypertensive medication. Gastrointestinal perforation occurred in 2% of BEAT patients and 1.9% of BRiTE patients.
The MAX clinical trial
The MAX study was an international trial sponsored by the Australasian Gastrointestinal Trials Group (AGITG) which randomized 471 patients with previously untreated, unresectable metastatic colorectal cancer who were considered suitable for initial monotherapy [Tebbutt et al. 2010] . The aim was to examine bevacizumabcontaining combination regimens of relatively low intensity which were suitable for elderly or medically unfit patients. Patients received either capecitabine alone (C), capecitabine plus bevacizumab (CB) or capecitabine plus mitomycin C plus bevacizumab (CBM). The primary endpoint was PFS, and the median follow up was 31 months. The median age of 68 years reflected the inclusion criteria. Median PFS was improved by the addition of bevacizumab (8.5 months for CB and 8.4 months for CBM) compared with capecitabine alone (5.7 months); C versus CB: HR 0.63, p < 0.001; C versus CBM: HR 0.59, p < 0.001. Median survival was not statistically different across the three arms: 18.9 months for C and CB, and 16.4 months for CBM. Of note, only 22% (C), 17% (CB) and 15% (CBM) of patients received all three cytotoxic agents at some point during their treatment, which may account for the relatively modest survival. The median number of cycles received was: 8 (range 136) for C, 10 (157) for CB and 9 (149) for CBM.
Toxicities were generally manageable, although patients who received longer durations of therapy experienced greater probability of specific toxicities. Grade 3/4 handfoot syndrome occurred in 16% (C), 26% (CB) and 28% (CBM) of patients, p < 0.03; however, when corrected for treatment duration there was no statistically significant difference. Similarly, grade 3/4 hypertension occurred in 0.6% (C), 3.8% (CB) and 6.3% (CBM), although this was not significant when corrected for treatment duration. Gastrointestinal perforation occurred in 0.6% (C), 1.9% (CB) and 0.6% (CBM) of patients, again not statistically significant. Sixty-day all cause mortality was 4% (C), 6% (CB) and 3% (CBM). Overall QOL ratings were similar across the three arms at baseline, at weeks 3 and 6, and from week 3 until progression (all p > 0.1).
The MAX study results were consistent with an earlier phase II study performed in patients over 65 years and considered unfit for first-line irinotecan [Kabbinavar et al. 2005] . In that study, 209 patients were randomized to either 5-FU/LV (Roswell Park regimen) plus placebo, or 5-FU/ LV plus bevacizumab. The primary endpoint was survival and the median age was 71 years. Median survival was not statistically different: 16.6 months (bevacizumab) versus 12.9 months (placebo), p ¼ 0.16. Median PFS was 9.2 months (bevacizumab) versus 5.5 months (placebo), p ¼ 0.0002. There was a trend towards improved response rate: 26.0% (bevacizumab) versus 15.2% (placebo), p ¼ 0.055. Sixty-day all-cause mortality was 5.0% (bevacizumab) compared with 13.5% (placebo). Grade 3/4 diarrhoea was similar: 39% versus 40%. Grade 3/4 hypertension occurred in 16% (bevacizumab) versus 3% (placebo). Gastrointestinal perforation occurred in 2% of bevacizumab patients only. QOL measures did not show any detrimental effect of bevacizumab on QOL; the time to deterioration in QOL was slightly longer as measured by TOI-C and FACT-C instruments in the bevacizumab group.
Summary of published trial data
This series of clinical trials has confirmed improved efficacy by adding bevacizumab to doublet or single-agent chemotherapy for metastatic colorectal cancer. These improvements, however, have not been across the board, and have not been of consistent magnitude with different chemotherapy backbones. Efficacy parameters in randomized phase III studies involving bevacizumab are summarized in Table 1 . The largest survival benefit in a randomized study was seen with the addition of bevacizumab to first-line IFL, a chemotherapy regimen which has since largely been abandoned due to its limited efficacy and poor toxicity profile. The amended BICC-C study suggested that FOLFIRI may be a superior chemotherapy backbone for bevacizumab compared with IFL. Significant survival improvement was documented by adding high-dose bevacizumab to second-line FOLFOX, however only a modest PFS advantage was observed when low-dose bevacizumab was added to first-line FOLFOX or XELOX. There have been attempts to reconcile these apparently contradictory results, particularly with regards to the optimal duration of therapy. There may be some merit to this hypothesis, as the duration of oxaliplatin-containing therapy was longer in the E3200 second-line study, compared with the NO16966 first-line study. The response rate in the first-line study was not increased by the addition of bevacizumab, whereas the response rate in the second-line study was clearly higher in the bevacizumab arm compared with the control arm. There are some data from previous trials suggesting that lack of objective response does not necessarily mean there is no survival benefit [Grothey et al. 2008a ]. Nevertheless, it could be that the bevacizumab dose is a more important factor than treatment duration, when combined with oxaliplatin-based chemotherapy. The non-randomised E2200 trial, which also studied high-dose bevacizumab, yielded similar response rates and PFS to the AVF2107 trial, despite the majority of patients receiving lower dose intensity irinotecanbased therapy (mIFL). Median survival was also impressive, suggesting that high-dose bevacizumab may be superior to low-dose bevacizumab even with irinotecan-based chemotherapy.
The MAX study demonstrated improved PFS in an older, less physically fit population by combining bevacizumab with capecitabine. Survival was not significantly improved, however, this may have been influenced by the inability of patients to tolerate further treatment, and hence the low rates of subsequent exposure to all three cytotoxic agents.
The toxicity profile of the bevacizumabchemotherapy regimens studied to date has been generally modest [Welch et al. 2010] .
Cumulative chemotherapy toxicities such as oxaliplatin-induced neuropathy and capecitabine-induced handfoot syndrome tend to occur more frequently when combined with bevacizumab due to the increased duration of therapy. Easily managed bevacizumab-specific toxicities, such as hypertension, proteinuria and others, occurred with predictable frequency. Severe toxicities such as gastrointestinal perforation occurred infrequently.
Dual targeting of VEGF and EGFR pathways with monoclonal antibodies
The potential for dual targeting of VEGF and epidermal growth factor receptor (EGFR) pathways in colorectal cancer was first suggested by the phase II BOND2 trial, and has since been evaluated in two phase III randomized trials [Saltz et al. 2007 ]. The CAIRO2 trial randomized 755 patients with previously untreated metastatic colorectal cancer to capecitabine, oxaliplatin and bevacizumab with or without cetuximab [Tol et al. 2009 ]. Both kRAS wildtype and kRAS mutated tumours were included. Disappointingly, the addition of cetuximab resulted in lower median PFS compared with chemotherapy plus bevacizumab: 9.4 months versus 10.7 months, p ¼ 0.01. There was no difference in median survival: 19.4 months versus 20.3 months, p ¼ 0.16. Subgroup analysis by kRAS mutation status revealed worse outcomes for patients with kRAS mutations treated with cetuximab. However, even patients with kRAS wild-type tumours treated with cetuximab did not achieve better PFS or survival compared to patients who received only chemotherapy plus bevacizumab.
More grade 3/4 hypertension was seen in the chemotherapy plus bevacizumab group: 14.8% compared with 9.3% in the cetuximab group, p ¼ 0.02. Gastrointestinal perforation occurred in 0.3% versus 1.6% of patients respectively, p ¼ 0.06. Apart from cetuximab-specific toxicities, all other toxicities were similar between the treatment arms. There were 532 patients evaluable for QOL. Overall QOL and global health status were similar between the arms at baseline; however, during treatment, both measures improved more in the no-cetuximab arm than the cetuximab-containing arm.
The Panitumumab Advanced Colorectal Cancer Evaluation (PACCE) had a similar design to CAIRO2 except that investigators could choose either oxaliplatin or irinotecan as the chemotherapy backbone [Hecht et al. 2009 ]. All patients received bevacizumab and were randomized to receive panitumumab or no additional treatment. Of 1053 patients, 823 received oxaliplatin-based therapy, while 230 patients received irinotecanbased therapy. The primary endpoint was PFS for the oxaliplatin-based cohort. As a result of a planned interim analysis, the trial was discontinued due to decreased PFS and increased toxicity in the panitumumab arm. In the oxaliplatin cohort, median PFS was 10.0 months for panitumumab and 11.4 months for the control arm. Median survival was 19.4 months for the panitumumab group and 24.5 months for the control group. For the irinotecan cohort, median PFS was 10.1 months for the panitumumab arm, and 11.7 months for the control arm. In the oxaliplatin cohort, kRAS mutational status was determined in 81% of patients. For kRAS wildtype patients, both median PFS and survival were superior in the control group compared to the panitumumab group.
Grade 3/4 hypertension occurred with similar frequency across all four treatment groups. Two grade 5 gastrointestinal perforations occurred in the oxaliplatinpanitumumab arm and none in any of the other treatment arms. Grade 3/4 skin toxicity and diarrhoea were predictably more frequent in the panitumumab groups.
On the basis of the CAIRO2 and PACCE trial results, dual targeting using an anti-EGFR antibody and bevacizumab is not recommended for patients with metastatic colorectal cancer. Several hypotheses have been proposed to explain the detrimental effect of adding an anti-EGFR antibody to bevacizumab and chemotherapy.
Need for further studies Several questions have yet to be answered regarding the optimal use of bevacizumab in metastatic colorectal cancer. The optimal duration of bevacizumab-containing therapy, whether as first-line chemotherapy and or as a second-line therapy, is not yet known. The uncertainty mainly relates to first-line treatment with FOLFOX plus bevacizumab, where a subgroup analysis suggested that efficacy was improved with longer duration of bevacizumab-containing therapy. The optimal bevacizumab dose is not yet defined, especially in combination with oxaliplatin-based therapy. It is possible that bevacizumab 10 mg/kg every 2 weeks is required for optimal benefit when combined with oxaliplatin. Although the currently available evidence suggests that commencing therapy with irinotecan plus bevacizumab is associated with the greatest survival benefit, the best sequence of chemotherapy regimens to be used alongside bevacizumab has not been tested in a randomized fashion.
The role of bevacizumab in peri-operative therapy for patients with potentially resectable colorectal liver metastases remains unknown. There are data suggesting that bevacizumab may be safely administered in the pre-operative setting up to 5 weeks prior to liver resection [Gruenberger et al. 2008] . Bevacizumab may protect against sinusoidal obstruction syndrome when administered pre-operatively with oxaliplatin-based chemotherapy [Klinger et al. 2009; Ribero et al. 2007 ]. Rates of metastasectomy in the aforementioned large randomized trials were low and/or comparable between no-bevacizumab and bevacizumab-containing arms; however, these trials were not designed to evaluate perioperative bevacizumab-containing therapy.
Another pressing problem is the need to identify response predictors for bevacizumab. There are very few data regarding biomarkers and response prediction for bevacizumab-containing therapy.
In a phase II study of 43 patients who received FOLFIRI plus bevacizumab, plasma cytokines and angiogenic factors (CAFs) were measured and correlated with clinical outcomes [Kopetz et al. 2010] . Elevated pre-treatment interleukin-8 was associated with shorter PFS. Several other CAFs were found to increase prior to development of radiographic disease progression suggesting possible roles in resistance to bevacizumab-containing therapy. Hurwitz and colleagues found that the addition of bevacizumab improved both PFS and response rate in both kRAS mutant and wild-type tumours in the pivotal AVF2107 trial [Hurwitz et al. 2009 ]. Only 230 of the total 813 patients were able to be analysed for kRAS mutational status. In this subgroup, a significant improvement in survival was only demonstrated for kRAS wild-type tumours: 27.7 months (IFL plus bevacizumab) versus 17.6 months (IFL), p ¼ 0.04.
Recommendations and conclusions
On the basis of the currently available data, we make the following recommendations. Medically fit patients with nonresectable advanced colorectal cancer should receive irinotecanbased chemotherapy (preferably FOLFIRI) plus bevacizumab. The role of bevacizumab for patients with resectable liver metastases is currently not well defined and there are insufficient data to make a clear recommendation for bevacizumab-containing therapy. For patients who are not medically suitable for combination chemotherapy, oral capecitabine plus bevacizumab is well tolerated and improves PFS. Patients who have not received a bevacizumab-containing regimen as first-line therapy benefit from secondline FOLFOX plus bevacizumab. However, until the results from prospective trials are available, potential benefits from the addition of bevacizumab to second-line chemotherapy are unproven.
The introduction of bevacizumab has increased both available options and potential complexity of systemic treatment for metastatic colorectal cancer. Oncologists need to carefully establish treatment goals with their patients prior to administration of bevacizumab-containing therapy. Careful selection of chemotherapy backbones with a view to likely tolerability, treatment duration and potential for metastasectomy should optimize clinical benefit with acceptable toxicity.
